BAT Hosts Successful CORESTA Global Tobacco Science Conference in Edinburgh

Oct.18.2024
BAT Hosts Successful CORESTA Global Tobacco Science Conference in Edinburgh
BAT successfully hosted the CORESTA global tobacco science conference in Edinburgh, focusing on harm reduction and public health opportunities.

On October 17, British American Tobacco (BAT) announced on their official website that the CORESTA Global Congress on Tobacco and Related Products Science was successfully held at the Edinburgh International Conference Center from October 13th to 17th. The event was hosted by BAT, and it brought together over 500 representatives from more than 30 countries, including businesses, research institutions, laboratories, associations, and regulatory bodies. The participants gathered to discuss the prospects of harm reduction in tobacco.


The conference, themed "Advancing Tobacco Harm Reduction through Scientific Collaboration," focused on ways to create smoke-free alternatives for billions of tobacco users. It not only facilitated international dialogue on scientific research related to tobacco and nicotine but also showcased research findings and discoveries from CORESTA members, providing crucial support for the transition from combustible tobacco to smoke-free alternatives.


During the opening ceremony, Danni Tower, Head of Scientific and Regulatory Affairs at the company, gave a keynote speech emphasizing the progress of BAT in advancing tobacco harm reduction agenda. She mentioned that scientific collaboration is crucial in expanding public awareness and acceptance of tobacco harm reduction, and highlighted BAT's commitment to sharing and exchanging world-class scientific research.


The CORESTA conference highlighted the importance of global scientific collaboration to maximize public health opportunities for tobacco harm reduction. We are proud to host such an important event and believe that if all stakeholders recognize the potential for tobacco harm reduction, positive changes could occur globally.


In order to achieve this goal, as discussed this week, there is a need for more open dialogue in the fields of science and regulation. Therefore, we have recently launched Omni™- offering thoughtful ideas for a smoke-free world- which is an open, evidence-based platform based on leading scientific research.


Other keynote speakers at the conference include global health advocate Derek Yach, who spoke on the topic of "New Generation Products Require New Generation Science and Regulation.


The speech at the CORESTA conference showcased the scientific advancements being made using new methods to accelerate harm reduction in tobacco. These advancements ranged from the application of genomics in agricultural science to the development of biomarkers in research, as well as the use of artificial intelligence tools to enhance our understanding of the reasons and effects of interventions. All public health agencies, including the World Health Organization (WHO), should collaborate with CORESTA scientists to expedite change.


BAT stated that the CORESTA conference is just another example of its commitment to promoting public health interests by reducing the harm caused by tobacco globally. The company continues to invest in the development of new smoke-free tobacco products, supported by cutting-edge scientific research and high standards, aimed at laying the foundation for a smoke-free world.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Florida HB 389 seeks statewide ban on smoking and vaping in public places and indoor workplaces
Florida HB 389 seeks statewide ban on smoking and vaping in public places and indoor workplaces
Florida lawmakers have introduced HB 389, a proposal to expand smoke-free protections by banning smoking and vaping in public places and enclosed indoor workplaces across the state. The bill broadens statutory definitions and outlines limited exceptions and compliance rules, with an effective date of July 1, 2026 if enacted.
Feb.10 by 2FIRSTS.ai
South Korean Court Strikes Down Health Levy on Vape Nicotine Liquids, Citing Disproportionate Penalties
South Korean Court Strikes Down Health Levy on Vape Nicotine Liquids, Citing Disproportionate Penalties
A Seoul court has annulled South Korea’s health-levy assessments imposed on multiple importers of nicotine liquids used for vaping. While the court agreed the nicotine could be treated as “tobacco” because it was found to be leaf-derived, it ruled the levy—stacked with other taxes and calculated on a blunt, volume-only basis—was so severe it effectively deprived businesses of the ability to operate, breaching constitutional proportionality and equality standards.
Jan.26 by 2FIRSTS.ai
Over 160 organizations urge Formula 1 to end all tobacco sponsorships, including nicotine pouches
Over 160 organizations urge Formula 1 to end all tobacco sponsorships, including nicotine pouches
On March 4, 2026, more than 160 public interest organizations worldwide sent a letter to Formula 1 urging it to expand its 2006 prohibition on cigarette sponsorships to include nicotine pouches and other tobacco products. The letter states that Philip Morris International sponsors Ferrari to promote ZYN pouches, while British American Tobacco sponsors McLaren with its Velo brand, with logos displayed on cars and drivers’ race suits and promoted on social media.
Mar.06 by 2FIRSTS.ai
Fiscal benefit, not health, strongest indicator for vape bans – Contributed by Samrat Chowdhery
Fiscal benefit, not health, strongest indicator for vape bans – Contributed by Samrat Chowdhery
Data shows 75% of nations with state stakes in tobacco trade ban modern substitutes compared to 10% in the free-market group. What is driving these divergent regulations?
Feb.04
UK Court Sentences Shrewsbury Retailer for Illegal Vape and Counterfeit Tobacco Sales
UK Court Sentences Shrewsbury Retailer for Illegal Vape and Counterfeit Tobacco Sales
A UK local authority has secured convictions against a Shrewsbury retailer and its former director for selling illegal disposable vapes, counterfeit tobacco and a nicotine vape to a minor, highlighting continued enforcement against non-compliant nicotine products.
Feb.05 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24